These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 2386954

  • 21. Suramin in adrenal cancer: modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect.
    La Rocca RV, Stein CA, Danesi R, Jamis-Dow CA, Weiss GH, Myers CE.
    J Clin Endocrinol Metab; 1990 Aug; 71(2):497-504. PubMed ID: 2380344
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Inhibition of the Tcf/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis.
    Leal LF, Bueno AC, Gomes DC, Abduch R, de Castro M, Antonini SR.
    Oncotarget; 2015 Dec 15; 6(40):43016-32. PubMed ID: 26515592
    [Abstract] [Full Text] [Related]

  • 25. Steroidogenesis in isolated cells and mitochondria of rat Snell adrenocortical carcinoma 494.
    Mason JI, Robidoux WF.
    Endocrinology; 1979 Nov 15; 105(5):1230-6. PubMed ID: 226350
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Androgen influences transforming growth factor-beta1 gene expression in human adrenocortical cells.
    Zatelli MC, Rossi R, degli Uberti EC.
    J Clin Endocrinol Metab; 2000 Feb 15; 85(2):847-52. PubMed ID: 10690900
    [Abstract] [Full Text] [Related]

  • 28. Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP).
    Haidan A, Hilbers U, Bornstein SR, Ehrhart-Bornstein M.
    Peptides; 1998 Feb 15; 19(9):1511-7. PubMed ID: 9864057
    [Abstract] [Full Text] [Related]

  • 29. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells.
    Ideyama Y, Kudoh M, Tanimoto K, Susaki Y, Nanya T, Nakahara T, Ishikawa H, Fujikura T, Akaza H, Shikama H.
    Jpn J Pharmacol; 1999 Feb 15; 79(2):213-20. PubMed ID: 10202857
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R.
    Lichtenauer UD, Shapiro I, Geiger K, Quinkler M, Fassnacht M, Nitschke R, Rückauer KD, Beuschlein F.
    Endocrinology; 2008 Mar 15; 149(3):1314-22. PubMed ID: 18063677
    [Abstract] [Full Text] [Related]

  • 36. Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line.
    Fallo F, Pilon C, Barzon L, Pistorello M, Pagotto U, Altavilla G, Boscaro M, Sonino N.
    Chemotherapy; 1998 Mar 15; 44(2):129-34. PubMed ID: 9551244
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. ACTH and PRL sensitivity of highly differentiated cell lines obtained by adrenocortical targeted oncogenesis.
    Ragazzon B, Lefrançois-Martinez AM, Val P, Tournaire C, Berger M, Gachancard-Bouya JL, Bègue RJ, Veyssière G, Martinez A.
    Endocr Res; 2004 Nov 15; 30(4):945-50. PubMed ID: 15666850
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.